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The Pharmaceuticalization of the Tobacco Industry
Yogi Hale Hendlin, PhD; Jesse Elias, MA; and Pamela M. Ling, MD, MPH
Is developing and legitimizing pharmaceutical-like,reduced-harm tobacco products giving the tobacco
industry a new lease on life? Cigarettes constitute more
than 90% of the industry's profits, and the number of
smokers is increasing worldwide with population
growth. Smoking prevalence is simultaneously declin-
ing, threatening cigarettes' long-term profitability.
Transnational tobacco companies (TTCs) aggressively
promote smoking in low- and middle-income countries
but have also diversified their product lines to in-
clude more socially acceptable alternative nicotine
products, marking an industry-wide shift (1, 2). This
pursuit of new, standardized, designer, possibly
government-certified nicotine products—a process we
call pharmaceuticalization—may fundamentally change
how policymakers and the public perceive both the to-
bacco industry and its products.
WHAT IS PHARMACEUTICALIZATION?
In medical ethics, pharmaceuticalization is “the
translation or transformation of human conditions, ca-
pabilities and capacities into opportunities for pharma-
ceutical intervention” (3). Applied to tobacco, pharma-
ceuticalization represents the tobacco industry's actual
and perceived transition into a pharmaceutical-like in-
dustry through the manufacture and sale of noncom-
bustible tobacco and nicotine products for smoking
cessation or long-term nicotine maintenance without
the testing and oversight required of traditional phar-
maceutical products. That TTCs pursue selling nicotine
products—such as ZONNIC nicotine gum, which is sold
in the United States through Reynolds American sub-
sidiary Niconovum, and the Voke nicotine inhaler and
e-Voke e-cigarettes, which were licensed by British
American Tobacco (BAT) subsidiary Nicoventures in the
United Kingdom—heralds a convergence between to-
bacco industry nicotine products and pharmaceutical
nicotine replacement therapy. Pharmaceuticalized to-
bacco products share 3 key elements with pharmaceu-
ticals: standardized dosing, sleek medical design, and
implicit or explicit certification or approval by relevant
health authorities (Figure).
Two false intertwined assumptions facilitate phar-
maceuticalization: Substantial numbers of “inveterate”
smokers cannot quit, and most smokers require phar-
macotherapy to do so. These premises may guide pol-
icy away from prevention or complete cessation, sup-
porting prolonged use of safer nicotine products.
Although exemplary efforts to control tobacco eschew
alliances with tobacco companies (4), harm reduction
accepts a nicotine maintenance industry, potentially re-
casting TTCs providing nicotine products as partners
with health institutions.
The endorsement of health authorities by certifying
noncombustible products as cessation devices (in the
United Kingdom) or modified-risk tobacco products
(MRTPs) in the United States validates TTC and
e-cigarette company claims and confers public legiti-
macy. New nicotine products lacking sanction by med-
ical authorities may benefit from a halo effect, whereby
their resemblance to pharmaceuticals leads consumers
to perceive them as such. Without new drug approval,
alternative nicotine products cannot be advertised as
cessation devices; nonetheless, consumers may regard
these as de facto nicotine replacement therapy ana-
logues. Vaping advocates and some public health or-
ganizations cast e-cigarettes as cessation aids regard-
less of certification by drug authorities. As such, the
industry assumes the mantle of medical legitimacy by
association.
AN INDUSTRY IN TRANSITION
All major TTCs have large investments in pharma-
ceuticalized tobacco products. Since 2008, Philip Mor-
ris International has spent more than $2 billion re-
searching reduced-risk products (1, 2). In 2016, it spent
another €500 million on its heat-not-burn product
iQOS and submitted a multimillion-page MRTP applica-
tion to the U.S. Food and Drug Administration in the
hopes of certifying it as a reduced-harm product. The
company ultimately aims “to replace cigarettes with
RRPs [reduced-risk products] as soon as possible,” fol-
lowing a “scientific assessment program . . . inspired by
standards and practices long adopted by the pharma-
ceutical industry” (2). A signal of pharmaceuticalization
as a broader trend, in 2016 the company also invested
$20 million in Syqe Medical, an Israeli manufacturer of
a medical marijuana vaporizer that allows physicians to
prescribe “therapeutic” doses of cannabis (5).
Reynolds American similarly sought to “migrate”
smokers “outside traditional tobacco [to] (Pharma) . . .
to cover tobacco dependence, beyond cessation” (6).
In 2017, BAT acquired Reynolds American for $49 bil-
lion, expressing specific interest in the company's next-
generation products, including its best-selling U.S.
e-cigarette brand, Vuse (7). Imperial Tobacco launched
the e-cigarette Puritane in 2014, whereas its subsidiary
Fontem Ventures purchased e-cigarette patents from
Dragonite International for $75 million and blu, the sec-
ond best-selling e-cigarette brand globally, in 2015. Ja-
pan Tobacco International bought U.K. e-cigarette
brand E-Lites' parent company Zandera in 2014; the
third-largest U.S. e-cigarette company, Logic Technol-
ogy Development; and in 2015 the heat-not-burn and
vaping company Ploom.
The U.K. National Health Service's approval of
BAT's e-cigarettes as prescription cessation devices is
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Figure. Pharmaceuticalized nicotine (and marijuana) products owned by transnational tobacco companies.
Company Sample Image Subsidiary and Products Date Notes
Altria
Group/PMI
PMI
iQOS heat-not-burn cigarette
(pictured top left)
NuMark
MarkTen XL e-cigarette
Verve
Verve lozenge
Green Smoke
Green Smoke e-cigarette
Nicocig
Nicolites e-cigarette
Vivid e-liquid
Altria Group/PMI invested in the
Syqe Medical marijuana inhaler
(pictured bottom left)*
2014
2014
2012
2014
2014
2016
PMI invested $20 million in the Israeli
pharmaceutical marijuana company
Syqe Medical, whose products claim to
“consistently deliver metered doses at
pharmaceutical-level precision.”
Reynolds 
American
Niconovum
ZONNIC gum, pouch, and spray
R.J. Reynolds Vapor
Vuse e-cigarette
(pictured)
2009
2013
ZONNIC is an FDA-approved NRT
product sold by a tobacco company.
Japan 
Tobacco 
International
Zandera (United Kingdom)
E-Lites e-cigarette
Logic Technology Development
Various e-cigarette brands
(pictured)
Ploom e-cigarette and
heat-not-burn products
2014
2015
2015
E-Lites is 1 of the top-selling e-
cigarettes in the United Kingdom.
Ploom was acquired by Japan Tobacco
International in 2015.
British 
American
Tobacco
Nicoventures
Vype e-cigarette
Nicovations
Voke inhaler†
e-Voke e-cigarette†
CHIC Group (Poland)
VOLISH, PI, Provog, Cottien,
and LiQueen e-cigarettes
British American Tobacco
glo iFuse tobacco heating
product
glo noncombustible cigarette
(pictured)
2013
2014
2015
2015
2015
2016
Vype e-cigarette is sold at Lloyd’s
Pharmacy in the United Kingdom
against the advice of the Royal
Pharmaceutical Society.
In 2014, Nicovations became the first
company to receive licenses for both
its nicotine inhaler (Voke) and, a year
later, its e-cigarette (e-Voke).
Imperial 
Tobacco
Fontem Ventures
blu e-cigarette
(pictured)
2014
2014
2015
Puritane e-cigarettes are available
exclusively at U.K. pharmacy chain
Boots against the advice of the Royal
Pharmaceutical Society.
Vuse is the best-selling e-cigarette in
the United States.
Puritane e-cigarette
Jai e-cigarette
FDA = U.S. Food and Drug Administration; NRT = nicotine replacement therapy; PMI = Philip Morris International.
* Image courtesy of Syqe Medical.
† Not yet released.
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the paradigm of tobacco industry pharmaceuticaliza-
tion (8). The U.K. Medicines and Healthcare products
Regulatory Agency announced in 2013 that all nicotine-
containing products, including e-cigarettes, would be
eligible for medical licenses. In 2014, BAT subsidiary
Nicovations was the first company to receive licenses
for its nicotine inhaler Voke and its e-cigarette e-Voke,
which would allow physicians in the United Kingdom to
prescribe these products.
IMPLICATIONS FOR HEALTH
The health consequences of pharmaceuticalization
are 3-fold. First, it contributes to the dilution and con-
fusion surrounding the real process and trust implied in
the imprimatur of legal prescription pharmaceuticals.
On the basis of the quality of current evidence, U.S.
health authorities do not recommend e-cigarettes for
cessation (9). Yet, these products are widely perceived
by patients and clinicians as cessation devices.
Second, pharmaceuticalization complicates the
regulatory process, expanding a class of products that
seem like drugs, devices, or a combination of both but
might not be subject to regulation as such. The U.S.
Food and Drug Administration's 2017 rule on tobacco
drugs and devices permits manufacturers to apply for
MRTP authorization with evidence that their products
verifiably reduce harm, whereas those making thera-
peutic claims require drug or device regulation (10).
However, look-alike tobacco products without thera-
peutic claims entering the market with only premarket
review or substantial equivalency may gain a reputation
for safety or cessation efficacy by association, bypass-
ing more stringent regulatory processes.
Third, pharmaceuticalization legitimizes the to-
bacco industry as a partner and producer of innovative
nicotine products, ignoring the ethics of both produc-
ing and profiting from addiction and its treatment (4).
By transitioning the cigarette business to the nico-
tine business, TTCs stand to profit from smokers, new
nicotine users, and would-be quitters. They seek to re-
habilitate their image by seeming responsive to public
health concerns and exonerate themselves from the re-
sponsibility of having addicted smokers by offering
long-term modified-risk nicotine maintenance. And
they ensure profitability amid increasingly strict regula-
tions while renormalizing the tobacco industry and nic-
otine use. Pharmaceuticalization represents the next
phase of the tobacco industry and a new threat to pub-
lic health.
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